# Trade Mark Journal No.2026/031 31 July 2026

## WO0000001927939 (5,9,10,42,44)

Office of origin: European Union Intellectual Property Office (EUIPO)

Date of International Registration:28 April 2026
Date of designation in the UK: 28 April 2026

International priority date claimed: 27 November 2025 (European Union Intellectual Property Office (EUIPO)) (019283360)

Class 5
  Diagnostic test reagents for medical purposes for prostate cancer testing; pharmaceutical preparations for treatment of cancer; reagents for use in diagnostic tests for medical purposes; diagnostic test materials for medical purposes; diagnostic preparations for medical purposes; diagnostic agents for medical use.
Class 9
  Downloadable software for calculating the risk of prostate cancer; downloadable computer programs for calculating the risk of prostate cancer; downloadable computer software for prostate cancer testing; downloadable application software for calculating the risk of prostate cancer; scientific research and laboratory apparatus for measuring, quantification and analysis of proteins and genetic material; medical training simulators for educational purposes in the field of prostate cancer; scientific research and laboratory instruments for detecting proteins and genetic material for medical research and training purposes; computer peripherals devices.
Class 10
  Medical instruments, namely, protein and genetic measuring instruments for medical diagnostic purposes; medical apparatus and instruments for the diagnosis, examination, monitoring and treatment of prostate cancer; medical testing apparatus and instruments for detecting and diagnosing prostate cancer; testing probes for medical diagnostic purposes; medical diagnostic tools for calculating prostate cancer risk.
Class 42
  IT integration services; computer software development, programming and implementation for others; website hosting services; software as a service (SaaS) featuring computer software for calculating prostate cancer risk scores; rental of computer software for use in calculating cancer risk; providing temporary use of online non-downloadable computer software for calculating prostate cancer risk scores; application service provider featuring computer software for calculating prostate cancer risk scores; scientific research and analysis in the field of prostate cancer; medical and pharmacological research services in the field of prostate cancer; conducting clinical trials for others in the field of prostate cancer; scientific and medical research in the field of oncology and urology; providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; providing information on clinical studies via an interactive website.
Class 44
  Human healthcare services, namely, disease management programs; medical services in the field of oncology and urology; medical diagnostic services in the field of oncology and urology; medical diagnostic testing services for prostate cancer; prostate cancer screening services; medical analysis services for the diagnosis and treatment of cancer and related diseases; providing online information services relating to medical and diagnostic tests, namely information regarding prostate cancer tests for diagnosis and treatment purposes; phlebotomy services; medical blood testing services; blood sampling and analysis for diagnostic or treatment purposes; providing medical information relating to prostate cancer test results; providing medical information relating to medical diagnostic test results; medical analysis services for diagnostic provided by medical laboratories; medical laboratory analysis services for the analysis of samples and blood samples taken from patients for diagnostic purposes; rental of medical equipment for use in human healthcare; medical consultancy services in the field of oncology and urology; providing medical information in the field of oncology and urology.

A3P Biomedical AB (publ)

Representative: BRANN AB, Sveavägen 63, SE-113 59 Stockholm, SWEDEN